


CLAIMS:

1. A peptide selected from the group having the formulae:



5 wherein X is PhAc, IndAc, Ibu, Nac, 1- or 2-Npr, or Fpr,

R¹ is Tyr or His,

R² is D-Arg or D-Cit,

R⁵ is Ile or Val,

R⁶ is Phe, Nal or Phe(Y), in which Y = F, Cl, Br,

10 R⁸ is Asn, Gln, Ser, Thr, Ala, D-Asn, D-Gln, D-Ser, D-Thr, Abu, D-
Abu, or Aib,

R⁹ is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr
(Me), Ser, Ala or Aib,

R¹⁰ is Tyr or Phe(Y), in which Y = H, F, Cl, Br, or OCH₃,

15 R¹² is Lys, D-Lys, or Orn,

R¹³ is Val or Nle,

R¹⁴ is Leu or Nle,

R¹⁵ is Gly, Ala, Abu, Nle or Gln,

R¹⁶ is Gln or Arg,

20 R¹⁸ is Ser or Nle,

R¹⁹ is Ala or Abu,

R²¹ is Lys or Orn,

R²² is Leu, Ala or Aib,

R²⁷ is Met, Leu, Nle, Abu, or D-Arg,

25 R²⁸ is Arg, D-Arg, Ser, Asn, Asp, Ala or Abu,

R²⁹ is Arg, D-Arg, Har or D-Har,

and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 selected from the group consisting of

30 (PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹)hGH-RH(1-29)
NH₂ Peptide 1

00140-512455

[IndAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 2

[PhAc⁰, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 3

5 [PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 6

[PhAc⁰, His¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 7

10 [Nac⁰, His¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 8

3. A compound of claim 1 having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 1

15 4. A compound of claim 1 having the formula [IndAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 2

5. A compound of claim 1 having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
20 Peptide 3

6. A compound of claim 1 having the formula [PhAc⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
25 Peptide 6

7. A compound of claim 1 having the formula [PhAc⁰, His¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 7

30 8. A compound of claim 1 having the formula [Nac⁰, His¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 8

091198 RV5 SHAL3.0-030

9. A method of suppressing excessive levels of GH in a patient in need of same which comprises administering said patient an effective amount of a compound of claim 1.

10. A method of treating a patient having a cancer carrying receptors for IGF-I or -II which comprises administering to said patient an effective amount of a compound of claim 1.

11. A method for inhibiting IGF-II levels in tumors (cancers) and the expression of mRNA for IGF-II in the same tumors, which comprises administering to said patient an effective amount of a compound of claim 1.